Mantle cell lymphoma · 16 regimens
Cost vs Efficacy · 9 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Ibrutinib monotherapy Variant #01 | — | R 81 964 | 28d | ~22.1 mo | ~30.3 mo | ~2 | ~R 163 929 PFS proxy · indirect | 2 |
Acalabrutinib monotherapy Variant #01 | — | R 79 217 | 28d | ~38.4 mo | — | ~2 | ~R 158 435 PFS proxy · indirect | 4 |
R-FCM Variant #01 | — | R 67 954 | 28d | — | — | ~6 | ~R 252 295 indirect | — |
Zanubrutinib monotherapy Variant #01 | — | R 65 750 | 28d | — | — | ~39 | ~R 2 564 255 PFS proxy · indirect | 4 |
Cladribine monotherapy Variant #03 | — | R 34 921 | 35d | — | — | ~1 | ~R 34 921 indirect | — |
Bendamustine and Rituximab (BR) Variant #01 | — | R 33 874 | 28d | ~51.3 mo | — | ~6 | ~R 203 245 PFS proxy · indirect | 4 |
R-HAD Variant #01 | — | R 27 812 | 21d | — | — | ~4 | ~R 111 247 indirect | — |
Fludarabine monotherapy Variant #05 | — | R 13 754 | 28d | ~5.2 mo | — | ~7 | ~R 96 278 PFS proxy · indirect | 1 |
BCHOP Variant #01 | — | R 4 429 | 21d | — | ~35.6 mo | ~8 | ~R 35 431 PFS proxy · indirect | 1 |
High-dose Cytarabine monotherapy (HiDAC) Variant #01 | — | R 3 498 | — | ~5.2 mo | — | ~1 | ~R 3 498 PFS proxy · indirect | 1 |
Chlorambucil monotherapy Variant #03 | — | R 2 355 | 28d | ~5.2 mo | — | ~13 | ~R 30 610 PFS proxy · indirect | 1 |
Lenalidomide monotherapy Variant #01 | — | R 2 178 | 28d | ~8.7 mo | — | ~24 | ~R 52 272 PFS proxy · indirect | 2 |
Gemcitabine monotherapy Variant #01 | — | R 1 672 | 21d | ~5.2 mo | — | ~7 | ~R 11 705 PFS proxy · indirect | 1 |
Intermediate-dose Cytarabine monotherapy (IDAC) Variant #01 | — | R 1 560 | 28d | ~5.2 mo | — | ~6 | ~R 9 359 PFS proxy · indirect | 1 |
Rituximab monotherapy Variant #09 Partial | — | — | 28d | ~5.2 mo | — | ~1 | — | 3 |
Temsirolimus monotherapy Variant #02 Partial | — | — | 28d | ~4.8 mo | ~23.5 mo | ~2 | — | 2 |
16 of 16 regimens shown